Lundbeck

Parkinson's disease
#Drug discovery #Lundbeck #Parkinson's

Phase Ib data in advanced Parkinson’s disease released as Phase II trial begins 

Lundbeck has announced results from an open-label Phase Ib trial evaluating Lu AF28996, a novel, investigational, oral prodrug of D1-like/D2-like dopamine receptor agonist, in people with advanced Parkinson’s disease experiencing motor symptoms sub-optimally controlled despite optimised non-invasive antiparkinsonian medication.    The results are being presented at the… Read More

#News

Hormones in the brain concept
#European Commission #Lundbeck #Neuroscience #Otsuka #Schizophrenia

Brexpiprazole’s EU approval extended to include adolescents

The European Commission (EC) has approved Otsuka’s Rxulti (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older.  The drug was previously approved in the European Union in 2018 for the treatment of schizophrenia in adults.  The EC based its approval on… Read More

#News #Regulatory

MRI of the brain
#epilepsy #Longboard Pharmaceuticals #Lundbeck #Mergers and acquisitions #Neurology

Acquisition to strengthen neuroscience pipeline

Lundbeck and Longboard Pharmaceuticals have announced an agreement for Lundbeck to acquire Longboard. Longboard is a clinical-stage biopharmaceutical company focused on developing novel medicines for neurological diseases. Its lead asset, bexicaserin, has shown encouraging anti-seizure reduction to date in preclinical and clinical studies, with its next-generation… Read More

#Business & Investment #News

Dementia
#Alzheimer's #Dementia #FDA #Lundbeck #Otsuka #Phase III trial

FDA approves first drug for agitation due Alzheimer’s dementia

Otsuka and Lundbeck’s Rexulti (brexpiprazole) has become the first pharmacological treatment to be approved in the US for agitation associated with dementia due to Alzheimer’s disease. The Food and Drug Administration (FDA) has approved the companies’ supplemental New Drug Application (sNDA). Agitation is a… Read More

#News #Regulatory